MRTX - Resolution Bioscience and Mirati Therapeutics tie-up in lung cancer setting

Resolution Bioscience and Mirati Therapeutics (MRTX) enter companion diagnostic tie-up where Resolution’s ctDx liquid biopsy technology will be used to help identify non-small cell lung cancer ((NSCLC)) patients who may benefit from Mirati’s investigational KRAS G12C inhibitor therapy.Cancers stemming from RAS mutations account for nearly a quarter of all human cancers and contribute to 1 million deaths per year worldwide, and the Resolution assay will be used to identify patients whose cancers are driven by the KRAS variant.Mirati’s investigational drug candidate adagrasib (MRTX849) is an orally available small molecule that potently and selectively inhibits the G12C substitution mutation.

For further details see:

Resolution Bioscience and Mirati Therapeutics tie-up in lung cancer setting